Second, whether IKBKE induces RCC progression and sunitinib resistance by regulating the AKT signaling pathway via alternative targets or affecting factors other than RRM2, such as NF-κB 24, EGFR 38, or even the immune microenvironment 39, deserves further exploration. The gene discussed is RRM2; the disease is renal cell carcinoma.